Table 2. Analyses Stratified By Long-Term Condition.
k | OR | (95% CI) | p | |
Necessity | ||||
Asthma | 7 | 2.610 | 1.802–3.780 | <0.001 |
Bipolar disorder | 2 | 1.624 | 0.739–3.567 | 0.227 |
Blood disorders | 3 | 1.512 | 0.580–3.944 | 0.398 |
Cancer | 2 | 2.313 | 1.190–4.496 | 0.013 |
Depression | 8 | 1.989 | 1.382–2.862 | <0.001 |
Diabetes | 6 | 1.502 | 0.930–2.425 | 0.096 |
Dialysis/end stage renal disease | 3 | 1.454 | 0.771–2.742 | 0.247 |
Epilepsy | 2 | 0.859 | 0.284–2.602 | 0.789 |
Glaucoma | 3 | 1.697 | 0.976–2.949 | 0.061 |
High cholesterol | 2 | 1.497 | 0.659–3.401 | 0.335 |
HIV | 9 | 1.742 | 1.242–2.444 | 0.001 |
Hypertension | 7 | 1.426 | 0.980–2.075 | 0.064 |
IBD | 3 | 1.775 | 1.560–2.020 | <0.001 |
Mixed sample | 11 | 1.504 | 1.249–1.810 | <0.001 |
Organ transplant | 5 | 2.875 | 1.561–5.294 | 0.001 |
Pain | 2 | 1.239 | 0.468–3.280 | 0.666 |
Rheumatoid arthritis | 5 | 3.277 | 1.106–9.708 | 0.032 |
Schizophrenia | 2 | 3.301 | 1.115–9.777 | 0.031 |
Stroke/CHD/acute coronary syndrome | 9 | 1.402 | 1.022–1.924 | 0.036 |
Concerns | ||||
Asthma | 6 | 0.406 | 0.304–0.541 | <0.001 |
Bipolar disorder | 2 | 0.410 | 0.250–0.672 | <0.001 |
Blood disorders | 3 | 0.764 | 0.545–1.073 | 0.121 |
Cancer | 2 | 0.771 | 0.411–1.445 | 0.417 |
Depression | 8 | 0.408 | 0.215–0.772 | 0.006 |
Diabetes | 6 | 0.450 | 0.202–1.003 | 0.051 |
Dialysis/end stage renal disease | 3 | 0.509 | 0.211–1.232 | 0.134 |
Epilepsy | 2 | 0.662 | 0.327–1.339 | 0.251 |
Glaucoma | 3 | 0.909 | 0.258–3.204 | 0.882 |
High cholesterol | 2 | 0.598 | 0.123–2.918 | 0.525 |
HIV | 9 | 0.619 | 0.465–0.824 | 0.001 |
Hypertension | 6 | 0.433 | 0.340–0.552 | <0.001 |
IBD | 3 | 0.612 | 0.536–0.698 | <0.001 |
Mixed sample | 11 | 0.423 | 0.339–0.501 | <0.001 |
Organ transplant | 4 | 0.486 | 0.356–0.503 | <0.001 |
Pain | 2 | 0.620 | 0.428–0.897 | 0.011 |
Rheumatoid arthritis | 5 | 0.608 | 0.385–0.962 | 0.033 |
Schizophrenia | 2 | 0.648 | 0.410–1.025 | 0.063 |
Stroke/CHD/acute coronary syndrome | 9 | 0.518 | 0.382–0.704 | <0.001 |
Note. CHD = coronary heart disease.